{"id":"https://openalex.org/W1869550436","doi":"https://doi.org/10.1200/jco.1999.17.2.697","title":"Phase I Study of Liposomal Vincristine","display_name":"Phase I Study of Liposomal Vincristine","publication_year":1999,"publication_date":"1999-02-01","ids":{"openalex":"https://openalex.org/W1869550436","doi":"https://doi.org/10.1200/jco.1999.17.2.697","mag":"1869550436","pmid":"https://pubmed.ncbi.nlm.nih.gov/10080616"},"language":"en","primary_location":{"id":"doi:10.1200/jco.1999.17.2.697","doi":"https://doi.org/10.1200/jco.1999.17.2.697","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.1999.17.2.697","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067468792","display_name":"Karen A. Gelmon","orcid":"https://orcid.org/0000-0003-4111-2757","observed_orcids":["https://orcid.org/0000-0003-4111-2757"]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"K. A. Gelmon","raw_affiliation_strings":["From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029597444","display_name":"A. Tolcher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"A. Tolcher","raw_affiliation_strings":["From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":null,"display_name":"A. R. Diab","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"A. R. Diab","raw_affiliation_strings":["From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070792731","display_name":"Marcel B. Bally","orcid":"https://orcid.org/0000-0002-1994-4787","observed_orcids":["https://orcid.org/0000-0002-1994-4787"]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"M. B. Bally","raw_affiliation_strings":["From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001384070","display_name":"Leanne Embree","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"L. Embree","raw_affiliation_strings":["From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047623272","display_name":"Norma J. Hudon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"N. Hudon","raw_affiliation_strings":["From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002331909","display_name":"Carole Dedhar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"C. Dedhar","raw_affiliation_strings":["From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000870634","display_name":"D. Ayers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"D. Ayers","raw_affiliation_strings":["From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065891328","display_name":"Andrea F. Eisen","orcid":"https://orcid.org/0000-0001-8037-9556","observed_orcids":["https://orcid.org/0000-0001-8037-9556"]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"A. Eisen","raw_affiliation_strings":["From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047007478","display_name":"B. Melosky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"B. Melosky","raw_affiliation_strings":["From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112985948","display_name":"C. Burge","orcid":"https://orcid.org/0009-0008-1590-9598","observed_orcids":["https://orcid.org/0009-0008-1590-9598"]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"C. Burge","raw_affiliation_strings":["From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":null,"display_name":"P. Logan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"P. Logan","raw_affiliation_strings":["From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I141945490"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110146267","display_name":"L.D. Mayer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"L. D. Mayer","raw_affiliation_strings":["From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the British Columbia Cancer Agency, Vancouver, University of British Columbia, and Inex Pharmaceuticals, Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I141945490"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":6.606,"has_fulltext":false,"cited_by_count":108,"citation_normalized_percentile":{"value":0.97834248,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"17","issue":"2","first_page":"697","last_page":"697"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.8148999810218811,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.8148999810218811,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.16699999570846558,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.0066999997943639755,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/liposomal-vincristine","display_name":"liposomal vincristine","score":1.0},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8799999952316284},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8379999995231628},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9259999990463257},{"id":"https://openalex.org/keywords/vincristine","display_name":"vincristine","score":0.5009999871253967},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.6679999828338623},{"id":"https://openalex.org/keywords/peripheral-neuropathy","display_name":"peripheral neuropathy","score":0.8429999947547913},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.7369999885559082},{"id":"https://openalex.org/keywords/anticancer-agents","display_name":"anticancer agents","score":0.652999997138977}],"concepts":[{"id":"https://openalex.org/C2779429289","wikidata":"https://www.wikidata.org/wiki/Q408977","display_name":"Vincristine","level":4,"score":0.897721529006958},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.85991370677948},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8546218872070312},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.670189380645752},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.460559219121933},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4348883032798767},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.41764023900032043},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41072559356689453},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4043712317943573},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.22485661506652832}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000972","descriptor_name":"Antineoplastic Agents, Phytogenic","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000972","descriptor_name":"Antineoplastic Agents, Phytogenic","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000972","descriptor_name":"Antineoplastic Agents, Phytogenic","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004337","descriptor_name":"Drug Carriers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008081","descriptor_name":"Liposomes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D014750","descriptor_name":"Vincristine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D014750","descriptor_name":"Vincristine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014750","descriptor_name":"Vincristine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.1999.17.2.697","doi":"https://doi.org/10.1200/jco.1999.17.2.697","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.1999.17.2.697","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:10080616","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10080616","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W39449442","https://openalex.org/W175938947","https://openalex.org/W1567569917","https://openalex.org/W1589787262","https://openalex.org/W1979616323","https://openalex.org/W1996331958","https://openalex.org/W2007792190","https://openalex.org/W2021679590","https://openalex.org/W2036839119","https://openalex.org/W2038400874","https://openalex.org/W2042968560","https://openalex.org/W2055402663","https://openalex.org/W2059054910","https://openalex.org/W2072582106","https://openalex.org/W2085093172","https://openalex.org/W2085133554","https://openalex.org/W2141086589","https://openalex.org/W2146109309","https://openalex.org/W2158449037","https://openalex.org/W2170952917","https://openalex.org/W2396603079","https://openalex.org/W2910261262","https://openalex.org/W4233026774"],"related_works":["https://openalex.org/W2383772991","https://openalex.org/W3152282520","https://openalex.org/W2888817688","https://openalex.org/W2059054910","https://openalex.org/W1790476719","https://openalex.org/W1992656294","https://openalex.org/W2088819306","https://openalex.org/W2007792190","https://openalex.org/W2004457388","https://openalex.org/W2085133554"],"abstract_inverted_index":{"PURPOSE:":[0],"A":[1,73],"phase":[2,25,127,246],"I":[3],"study":[4],"of":[5,31,65,75,78,89,165,168,207,229,235],"vincristine":[6,33,91,108],"encapsulated":[7],"inside":[8],"120-nm-diameter":[9],"distearoylphosphatidylcholine-cholesterol":[10],"liposomes":[11],"was":[12,117,150,180,195],"performed.":[13],"The":[14,87,223],"primary":[15],"objectives":[16],"were":[17,44,50,80,95,105,134,140,155,214],"to":[18,55,111,225],"determine":[19],"the":[20,120,126,135],"maximum-tolerated":[21],"dose":[22,71],"(MTD),":[23],"recommended":[24,129],"II":[26,128,247],"dose,":[27],"toxicity,":[28],"and":[29,46,60,122,132,145,213],"pharmacokinetics":[30,88],"liposomal":[32],"(ONCO-TCS).":[34],"PATIENTS":[35],"AND":[36],"METHODS:":[37],"Twenty-five":[38],"patients":[39,69,153],"with":[40,63,107,157,170,185,218],"histologically":[41],"confirmed":[42],"malignancies":[43],"enrolled":[45],"assessable.":[47],"Vincristine":[48],"doses":[49,109,158,171,228],"increased":[51],"from":[52],"0.5":[53],"mg/m2":[54,62,116,124,161],"1.0,":[56],"1.5,":[57],"2.0,":[58],"2.4,":[59],"2.8":[61,112],"cohorts":[64],"three":[66],"or":[67,220],"more":[68],"per":[70],"level.":[72],"total":[74,90,208],"64":[76],"courses":[77],"ONCO-TCS":[79,239],"administered":[81],"intravenously":[82],"once":[83],"every":[84],"3":[85],"weeks.":[86],"content":[92],"in":[93,163,182,197,244],"plasma":[94],"determined":[96],"using":[97],"a":[98,183,245],"high-performance":[99],"liquid":[100],"chromatography":[101],"method.":[102],"RESULTS:":[103],"Patients":[104],"treated":[106,156],"up":[110],"mg/m2;":[113],"however,":[114],"2.4":[115],"defined":[118],"as":[119,125,172,174,231,233],"MTD":[121],"2.0":[123,166],"dose.":[130],"Pain":[131],"obstipation":[133],"dose-limiting":[136],"toxicites.":[137],"Other":[138],"toxicities":[139],"fever,":[141],"rigors,":[142],"fatigue,":[143],"myalgias,":[144],"peripheral":[146],"neuropathy.":[147],"Hematologic":[148],"toxicity":[149,219],"mild.":[151],"All":[152],"who":[154],"above":[159],"1.5":[160],"received":[162],"excess":[164],"mg":[167],"vincristine,":[169,209,230],"high":[173],"6.2":[175],"mg.":[176],"One":[177],"partial":[178,192],"response":[179,189,193],"seen":[181,196],"patient":[184],"pancreatic":[186],"cancer.":[187],"Tumor":[188],"not":[190,215],"meeting":[191],"criteria":[194],"two":[198],"other":[199],"patients.":[200],"Pharmacokinetic":[201],"studies":[202],"revealed":[203],"significantly":[204],"elevated":[205,227],"concentrations":[206],"but":[210],"parameters":[211],"varied":[212],"directly":[216],"correlated":[217],"response.":[221],"CONCLUSION:":[222],"ability":[224],"administer":[226],"well":[232],"indications":[234],"efficacy,":[236],"suggests":[237],"that":[238],"warrants":[240],"further":[241],"clinical":[242],"investigation":[243],"setting.":[248]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}